August 11, 2010

Synutra Provides Update on Infant Formula Allegations

Ministry of Health (MOH) explains no direct links between claims and Synutra's infant formula

QINGDAO, China and ROCKVILLE, Md., Aug 11, 2010 /PRNewswire via COMTEX News Network/ -- Synutra International, Inc. (Nasdaq: SYUT), a leading infant formula company in China and a producer, marketer and seller of nutritional products for infants, children and adults, today released the following public comment in response to a media report in China which linked hormone levels in the Company's milk powder with alleged premature development and sexual precocity.

Mr. Liang Zhang, Chairman and CEO of Synutra stated, "Since the initial speculation in reports that our products were responsible for premature development and precocity in children, there has been a tremendous increase in commentary in the press relating to this incident such as the People's Daily and Bloomberg. The media is increasingly relaying a more balanced take on the reality that there is no scientific evidence supporting the allegation that our products are responsible for these claims."

"We are seeing many industry experts also speak out about the lack of scientific evidence between infant formula and these claims. The recent press conference by the Ministry of Health (MOH) communicated that a definitive cause for premature development in the infant cases submitted could not be determined and that there are many possible contributing factors, which may cause premature development. These points are both positive for us and are in-line with our belief that Synutra products are safe and in no way related to these claims."

"Furthermore, we are in the process of taking legal action and are evaluating the various timing, jurisdiction and channels through which we may protect our brand. We intend to prosecute the parties responsible for these accusations to the furthest extent possible. While we offer our sympathy to any families experiencing health challenges, we firmly believe that our products are not involved in the claims recently made, and we feel this media event will pass. We firmly believe they will illustrate our unwavering product quality and commitment to consumer safety."

The Company will continue to proactively provide updates on the situation. To ensure access to the most updated information, the Company has created a "Synutra in the News" tab on the Company's IR website ( ), which contains links to the Company's most recent public statements and media articles.

About Synutra International, Inc.

Synutra International Inc. (Nasdaq: SYUT) is a leading infant formula company in China. It principally produces, markets and sells its products under the "Shengyuan" or "Synutra" name, together with other complementary brands. It focuses on selling premium infant formula products, which are supplemented by more affordable infant formulas targeting the mass market as well as other nutritional products and ingredients. It sells its products through an extensive nationwide sales and distribution network covering 30 provinces and provincial-level municipalities in China. As of June 30, 2010, this network comprised over 560 independent distributors and over 1,000 independent sub-distributors who sell Synutra products in over 74,000 retail outlets.

Forward-looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on our current expectations, assumptions, estimates and projections about Synutra International Inc. and its industry. All statements other than statements of historical fact in this release are forward-looking statements. In some cases, these forward-looking statements can be identified by words or phrases such as "anticipate," "believe," "continue," "estimate," "expect," "intend," "is/are likely to," "may," "plan," "should," "will," "aim," "potential," "continue," or other similar expressions. The forward-looking statements included in this press release relate to, among others, Synutra's goals and strategies; its future business development, financial condition and results of operations; the expected growth of the nutritional products and infant formula markets in China; market acceptance of the Company's products; adverse effects associated with the melamine contamination incident; Synutra's expectations regarding demand for its products; Synutra's ability to stay abreast of market trends and technological advances; competition in the infant formula industry in China; PRC governmental policies and regulations relating to the nutritional products and infant formula industries, and general economic and business conditions in China. These forward-looking statements involve various risks and uncertainties. Although Synutra believes that the expectations expressed in these forward-looking statements are reasonable, these expectations may turn out to be incorrect. Synutra's actual results could be materially different from the expectations. Important risks and factors that could cause actual results to be materially different from expectations are generally set forth in the "Item 1. Business," "Item 1A. Risk Factors," "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations," and other sections in Synutra's Form 10-K filed with the Securities and Exchange Commission on June 9, 2010. The forward-looking statements are made as of the date of this press release. Synutra International Inc. undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which the statements are made or to reflect the occurrence of unanticipated events.

SOURCE Synutra International, Inc.

Copyright (C) 2010 PR Newswire. All rights reserved

Close window | Back to top

Copyright 2017 Synutra International, Inc.